Related Experiment Videos
Kinetics of intravenous phenytoin in children
Insights
Single-dose intravenous phenytoin effectively treats status epilepticus in pediatric patients. This anticonvulsant medication demonstrated safety and efficacy in seizure eradication and prevention, maintaining therapeutic levels.
Area of Science:
- Pediatric Neurology
- Clinical Pharmacology
Background:
- Status epilepticus is a medical emergency requiring prompt treatment.
- Intravenous phenytoin is a common anticonvulsant, but its use in pediatric populations requires careful dosing and monitoring.
Purpose of the Study:
- To evaluate the efficacy and safety of single-dose intravenous phenytoin for status epilepticus in pediatric patients.
- To assess the pharmacokinetic profile of phenytoin in children, including volume of distribution and metabolic rate.
Main Methods:
- A cohort of pediatric patients with status epilepticus received a single intravenous dose of phenytoin.
- Pharmacokinetic parameters, including volume of distribution and Vmax (maximal rate of metabolism), were analyzed.
- Serum concentrations and clinical outcomes were monitored.
Main Results:
- Phenytoin effectively eradicated seizures in 12 of 13 patients within 3 minutes.
- No adverse effects were observed in any of the 24 treated patients.
- Therapeutic serum concentrations were maintained for over 10 hours in 15 patients, with age-dependent changes in volume of distribution noted.
Conclusions:
- Single-dose intravenous phenytoin is a safe and effective treatment for status epilepticus in pediatric patients.
- The pharmacokinetic properties of phenytoin in children vary with age, influencing dosing and therapeutic drug monitoring.
- Further research into age-specific dosing strategies may optimize phenytoin therapy in pediatric epilepsy.
Abstract:
Single-dose intravenous phenytoin (9.4-21.3 mg/kg) effectively eradicated seizures within 3 minutes in 12 out of 13 patients in status epilepticus. Eleven additional patients were treated prophylactically. No adverse effects were observed and neurological status was unaltered in all 24 cases. Phenytoin volume of distribution was found to decline significantly with age from 1.6 L/kg at 1 year to 0.6 at 10 years (P less than 0.01). Estimates of Vmax, the maximal rate of phenytoin metabolism, were obtainable in 8/24 patients and were in the expected range (10.6 +/- 4.2 mg/kg/day) for their age (6.6 +/- 2.8 years). Therapeutic serum concentrations (initial post distribution values 17.9 +/- 9.0 micrograms/ml) were maintained for more than 10 hours in 15/24 patients. Single-dose intravenous phenytoin is both effective and safe in the treatment and prevention of epileptic seizures in pediatric patients.